Close Menu

Cracking the Market

Philadelphia-based Mylan and India-based Biocon are teaming up to develop generic biotech drugs. "It makes sense that Mylan, which is an expert in making generic copies of traditional drugs, would partner with an outside firm that focuses on biotech. By the same token, cracking the market for generic biotechs in the developed world might also be tricky - so it makes sense that an Indian firm might want a U.S. partner," says the Wall Street Journal Health Blog.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.